Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.
You may also be interested in...
OTC Switch Criteria For Chronic Illnesses, Risk Factors Differ - DeLap
Prescription drugs that treat risk factors, rather than a chronic illness, may not be ideally suited for Rx-to-OTC switches due to the danger of side effects, FDA's Robert DeLap, MD/PhD, suggested at the Drug Information Association annual meeting in San Diego June 12-13.
OTC Switch Criteria For Chronic Illnesses, Risk Factors Differ - DeLap
Prescription drugs that treat risk factors, rather than a chronic illness, may not be ideally suited for Rx-to-OTC switches due to the danger of side effects, FDA's Robert DeLap, MD/PhD, suggested at the Drug Information Association annual meeting in San Diego June 12-13.
OTC Switch Criteria For Chronic Illnesses, Risk Factors Differ - DeLap
Prescription drugs that treat risk factors, rather than a chronic illness, may not be ideally suited for Rx-to-OTC switches due to the danger of side effects, FDA's Robert DeLap, MD/PhD, suggested at the Drug Information Association annual meeting in San Diego June 12-13.